| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3977491 | Brachytherapy | 2006 | 6 Pages |
Abstract
The data support HDRB boost as a potential means of dose escalation in prostate cancer. Significant findings using the ACD need to be validated with contemporary biochemical failure definitions. Prospective trials to optimize fractionation and evaluate outcomes in comparison to contemporary EBRT techniques are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Johann I. Tang, Scott G. Williams, Keen Hun Tai, Joanne Dean, Gillian M. Duchesne,